FIG. 2.

Estimated cumulative probability for incident advanced liver fibrosis (fibrosis-4 > 3.25) among persons with HIV/hepatitis C virus coinfection stratified by direct-acting antiviral treatment status, the HIV Outpatient Study, 2010–2020.

Note: Cox regression wilh covariates adjustment for age, sex, and Fib-4 score at index date for patients with no Fib-4 score >3.25 one year prior to index date (n=235). Index date is the DAA prescription date for ihe DAA- treated group and propensity score matched pseudo date of DAA prescription for DAA-nalïve group, respectively.